Biocardia- CellProThera & SlngXpand Collaborates to Develop and Commercialize CD34+ Stem Cells in Singapore for Myocardial Infarction
Shots:
- SlngXpand will conduct clinical studies of expanded in vitro expanded peripheral blood CD34+ stem cells- CellProThera will fund the clinical studies and to receive exclusive commercialization rights of Biocardia’s Helix Biotherapeutic Delivery System in Singapore
- Biocardia to get royalties on sales of product from CellProThera. The expanded CD34+ stem cells are processed by StemXpand Technology and delivered by Helix Biotherapeutic Delivery System in patients under treatment for Myocardial Infarction
- Biocardia’s Helix Biotherapeutic is percutaneous catheter delivery system for the delivery of cell and gene based therapies for cardiovascular disorders
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
